The test-negative study design is often used to estimate vaccine effectiveness in influenza studies, but it has also been proposed in the context of other infectious diseases, such as cholera, dengue, or Ebola. It was introduced as a variation of the case-control design, in an attempt to reduce confounding bias due to health-care-seeking behavior, and has quickly gained popularity because of its logistic advantages. However, examination of the directed acyclic graphs that describe the test-negative design reveals that without strong assumptions, the estimated odds ratio derived under this sampling mechanism is not collapsible over the selection variable, such that the results obtained for the sampled individuals cannot be generalized to the whole population. In this paper, we show that adjustment for severity of disease can reduce this bias and, under certain assumptions, makes it possible to unbiasedly estimate a causal odds ratio. We support our findings with extensive simulations and discuss them in the context of recently published cholera test-negative studies of the effectiveness of cholera vaccines.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/aje/kwab066 | DOI Listing |
Sci Rep
January 2025
Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Abassia, Cairo, Egypt.
Some patients with neuromyelitis optica spectrum disorder (NMOSD)-like symptoms test negative for anti-aquaporin-4 (anti-AQP4) antibodies. Among them, a subset has antibodies targeting myelin oligodendrocyte glycoprotein (MOG), a condition now termed MOG antibody-associated disease (MOGAD). MOGAD shares features with NMOSD, like optic neuritis and myelitis, but differs in pathophysiology, clinical presentation, imaging findings, and biomarkers.
View Article and Find Full Text PDFPLoS One
January 2025
Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
Introduction: Most studies on risk factors for a SARS-CoV-2 infection were conducted in the pre-vaccination era with many non-pharmaceutical prevention measures in place. We investigated risk factors for symptomatic SARS-CoV-2 infections in vaccinated persons in a period with a varying degree of prevention measures.
Methods: In a test-negative case control study among vaccinated adults attending community COVID-19 testing locations between June 1st 2021 till February 28th 2022, we compared symptomatic cases with symptomatic controls (to study risk factors specific for SARS-CoV-2) and with asymptomatic controls (to study risk factors that could apply to respiratory infections in general).
Vaccines (Basel)
November 2024
Mutala Trust, Harare, Zimbabwe.
Background/objectives: The COVID-19 pandemic has significantly impacted global health, with varying vaccine effectiveness (VE) across different regions and vaccine platforms. In Africa, where vaccination rates are relatively low, inactivated vaccines like BBIP-CorV (Sinopharm) and Coronovac (Sinovac) have been widely used. This study evaluated the real-world effectiveness of licensed inactivated COVID-19 vaccines in Zimbabwe during a period dominated by Omicron variants.
View Article and Find Full Text PDFInt J Mol Sci
December 2024
College of Environmental Science and Engineering, Yangzhou University, Yangzhou 225127, China.
Primary biliary cholangitis (PBC) is a chronic disease, the prevalence of which has been increasing in recent years. And the prevalence of patients who test negative with existing diagnostic techniques remains high. It was found that the antigenic BCOADC-E2 protein could detect patients with a negative original test.
View Article and Find Full Text PDFClin Infect Dis
January 2025
Influenza Division, US Centers for Disease Control and Prevention, Atlanta, GA, USA.
Background: The 2023-24 U.S. influenza season was characterized by a predominance of A(H1N1)pdm09 virus circulation with co-circulation of A(H3N2) and B/Victoria viruses.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!